1. Introduction
===============

IgA nephropathy (IgAN) is one of the most common primary chronic glomerular diseases worldwide, especially in Asia.^\[[@R1]\]^ The major pathologic feature is predominant IgA deposits in the glomerular mesangium, which are highly variable in clinical presentation and outcome.^\[[@R2]\]^ In 20% to 40% of patients with IgAN, slow progression to end stage renal disease (ESRD) occurs over 20 years from diagnosis.^\[[@R3]\]^ The majority of clinical trials and guidelines have focused on patients with active disease characterized as proteinuria greater than 1 g daily.^\[[@R4]\]^ No study has analyzed treatment of IgAN patients with proteinuria \< 1 g/d. Given that corticosteroids or immunosuppressants are widely used in patients that present with heterogeneous clinical and pathological disease manifestation,^\[[@R5],[@R6]\]^ we performed this study to analyze the safety and efficacy of steroids or immunosuppressants in IgAN patients with proteinuria \< 1 g/d.

2. Methods
==========

2.1. Study participants
-----------------------

Three hundred forty adult patients (33.15 ± 9.22 years) with newly diagnosed biopsy-proven IgAN were retrospectively enrolled in this study between December 2007 and February 2016 from 4 Chinese study centers (West China Hospital of Sichuan University, Affiliated Hospital of Zunyi Medical College, the Third Hospital of Zigong City, and People\'s Hospital of Mianzu City). Patients with proteinuria \< 1 g/d at biopsy were included. The exclusion criteria were as follows:

1.  systemic diseases such as ankylosing spondylitis, systemic lupus erythematosus (SLE), diabetes mellitus, Henoch--Schönlein purpura, liver cirrhosis, and others;

2.  follow-up period \< 12 months before reaching the study\'s defined endpoint;

3.  missing data during follow-up;

4.  history of kidney transplantation or use of corticosteroids, immunosuppressants, or fish oil prior to renal biopsy.

Treatment regimen was selected based on patients' willingness and doctors' experience. Every patient signed written informed consent. This study adhered to the Helsinki Declaration and was approved by the Ethics Committee of West China Hospital of Sichuan University. This study was registered at the Clinical Trail Registration Center of China ([www.ClinicalTrials.gov](http://www.clinicaltrials.gov/); TCTR20180313004).

2.2. Follow-up and data collection
----------------------------------

The follow-up period refers to the interval between renal biopsy and the last outpatient visit, death, ESRD, or reaching the defined end point. At the time of biopsy and during follow-up, sex, age, systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine (Scr), estimated glomerular filtration rate (eGFR), serum albumin (Alb), 24-hour proteinuria, kidney pathology data, and the use of antihypertensive drugs, angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), corticosteroids, or immunosuppressants were recorded. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Renal biopsy was reviewed by an experienced pathologist and nephrologist using the Oxford Classification of IgAN:^\[[@R7]\]^ mesangial score \< 0.5 or \>0.5 (M0/M1), segmental glomerulosclerosis absent or present (S0/S1), endocapillary hypercellularity absent or present (E0/E1), tubular atrophy/ interstitial fibrosis \< 25%, 26% to 50%, \>50% (T0/T1/T2), and cellular or fibrocellular crescents absent, or a crescent in at least 1 glomerulus, or crescents in at least 25% of glomeruli (C0/C1/C2). Specially, global glomerulosclerosis (G) was defined as a hyaline deposition or scarring lesion occurring in more than 50% of any 1 glomerulus and was graded according to the percentage of global glomerulosclerosis: G0 (≤25% of glomeruli), G1 (26--50% of glomeruli), and G2 (\>50% of glomeruli).

2.3. Clinical responses and outcomes
------------------------------------

Patients were divided into 2 groups according to therapeutic strategy. Patients in the supportive care group (SC) received only the optimal dose of ACEI or ARB to achieve target blood pressure (BP \< 130/80 mm Hg). Patients in the corticosteroids or immunosuppressant group (IT) received optimal ACEI/ARB plus corticosteroids (0.5--1 mg/kg/d prednisone or equal dose of methylprednisolone, tapering down within 6--8 months) with or without immunosuppressant therapy (2 mg/kg/d cyclophosphamide for 3 months or 1--2 g/d mycophenolate mofetil for 6--8 months).

Responses to therapy included complete remission (CR), partial remission (PR), no response (NR), and ESRD. CR was defined as urinary protein excretion \< 0.5 g/24 h with an eGFR decrease less than 10% of baseline. PR was defined as decreased proteinuria \>50% of baseline with eGFR decreased to less than 10% of baseline. NR was defined as decreased proteinuria \< 50% of baseline or eGFR decreased to \>10% of baseline. ESRD was defined as eGFR \< 15 mL/min/1.73 m^2^, chronic dialysis, or renal transplantation. The primary study endpoint was a renal function decline of \>50% in eGFR and/or ESRD.

2.4. Statistical analyses
-------------------------

Categorical variables are presented as frequencies and percentages and were compared using Fisher and Chi-squared tests. Continuous variables are expressed as mean ± standard deviation (SD) and analyzed using a *t* test, 1-way ANOVA, or Kruskal--Wallis *H* test, as appropriate. Kidney survival for each group was estimated using the Kaplan--Meier method with a log-rank test. Univariate and multivariate Cox proportional hazard models were run to assess the influence of clinical and pathological variables on renal outcomes. IBM SPSS Statistics 22.0 was used for statistical analysis and a *P* value \< .05 was considered significant.

3. Results
==========

3.1. Baseline characteristics
-----------------------------

The patients' baseline characteristics are presented in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. A total of 340 IgAN patients were screened and 295 patients with urine protein \< 1 g/24 h at biopsy were included. Forty-five patients were excluded according to the following exclusion criteria: hepatitis (n = 13), diabetes mellitus (n = 6), Henoch--Schönlein purpura (n = 1), ankylosing spondylitis (n = 4), SLE (n = 1), pulmonary tuberculosis (n = 1), thalassemia (n = 1), hypothyroidism (n = 1), prior thyroid cancer operation (n = 1), multiple myeloma (n = 1), thyroid carcinoma (n = 1), tonsillectomy (n = 2), and inadequate data (n = 12) (Fig. [1](#F1){ref-type="fig"}). Patients were followed for 49.46 ± 24.35 months. Among the 295 patients, 194 (65.76%) had stage 1 CKD, 75 (25.42%) had stage 2 CKD, and 26 (8.82%) had stage 3 CKD. Two hundred forty-six patients (83.39%) were assigned to the SC group and 49 patients (16.61%) were assigned to the IT group according to therapeutic strategy. Twenty-five patients in the IT group received corticosteroid mono-therapy and the remaining 24 patients were treated with corticosteroids and immunosuppressant therapy. At baseline, patients in the IT group presented with significantly lower eGFR, higher 24-hour proteinuria, and more severe renal pathologic lesions (M, S, T, C, and G) than those in the SC group. Additionally, we observed significant differences in hypertension, SBP, DBP, serum creatinine, eGFR, 24-hour proteinuria, and pathologic lesion M, S, T, and G scores among patients in CKD stage 1, 2, and 3. At the end of follow-up, there were no significant differences between the SC and IT groups in serum creatinine (86.19 ± 63.49 vs 88.08 ± 30.28, *P* = .839), 24-hour urine protein (0.53 ± 0.74 vs 0.49 ± 0.44, *P* = .727), or serum albumin (43.12 ± 3.12 vs 42.94 ± 3.02, *P* = .714).
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Baseline clinicopathological characteristics of IgAN patients in different theropies.
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Baseline clinicopathological characteristics of IgAN patients in different CKD stages.
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![Flow diagram. AS = ankylosing spondylitis, DM = diabetes mellitus, CKD = chronic kidney disease, SC = supportive care group, IT = corticosteroids/ immunosuppressive therapy group, CR = complete remission, PR = partial remission, NR = no response, ESRD = end stage renal disease.](medi-99-e20513-g003){#F1}

3.2. Clinical response and outcome
----------------------------------

At the end of follow-up, 224 patients (75.9%) achieved CR, 7 patients (2.4%) achieved PR, 55 patients (18.6%) had NR, and 9 patients (3.1%) reached ESRD. Eleven patients (3.7%) reached the combined study endpoint (Table [3](#T3){ref-type="table"}). However, no significant differences were observed between the SC and IT groups with respect to CR (76.4% vs 73.5%, *P* = .659), PR (2.0% vs 4.1%, *P* = .329), NR (18.3% vs 20.4%, *P* = .728), and ESRD (3.3% vs 2.0%, *P* = 1.000). Additional analyses of stage 1 CKD patients yielded similar results, with 149 of 246 SC group patients (89.2%) and 21 of 49 IT group patients (77.8%) achieving CR by the final visit (*P* = .113). Moreover, there were no stage 1 CKD patients (at baseline) that ended in ESRD during the follow-up period. There was also no significant difference between the SC and IT group CR ratios in stage 2 CKD patients (58.3% vs 66.7%, *P* = .556). A higher CR rate was observed in stage 3 CKD patients in the IT group (71.4%) compared to the SC group (21.1%) (*P* = .028), but the small number of patients may have limited the significance of this result. No statistical difference in ESRD rate was observed in stage 1--3 CKD patients. Moreover, there was no statistically significant difference in the number of patients that reached the combined endpoint in each group (9 patients in the SC group (3.7%) and 2 patients in the IT group (4.1%), *P* = 1.000).

###### 

Response and outcome.
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3.3. Renal survival
-------------------

No significant difference was observed between patients in the SC and IT groups with respect to composite endpoint probability calculated from Kaplan--Meier analysis (93.7% vs 94.1%, *P* = .808). Similarly, renal survival rates in the SC group and IT group were 97.6% vs 97.9% (*P* = .529) after 3 years and 94.9% versus 94.1% (*P* = .392) after 5 years (Fig. [2](#F2){ref-type="fig"}). As shown in Figure [3](#F3){ref-type="fig"}A, renal survival rates were remarkably higher in early stage CKD patients (CKD 1 \> CKD 2 \> CKD 3, *P* \< .001). However, we observed no benefits of immunosuppressant treatment in renal survival in stage 1, 2, or 3 CKD patients with mild proteinuria (*P* = .725, .223, or .160; Fig. [3](#F3){ref-type="fig"}B and D). Segmental sclerosis and glomerulosclerosis subgroup analysis showed no significant differences between SC and IT group patients in S0 (99.4% vs 95.2%, *P* = .105), S1 (90.9% vs 96.4%, *P* = .370), G0 (99.5% vs 100.0%, *P* = .741), or G1/G2 (70.4% vs 88.2%, *P* = .247).

![Kaplan--Meier analysis for the composite endpoint probability in SC and IT groups. Note: the composite endpoint was a 50% decline in eGFR and/or ESRD. SC = supportive care group, IT = corticosteroids/immunosuppressive therapy group.](medi-99-e20513-g005){#F2}

![Kaplan--Meier analysis for the composite endpoint probability in different CKD stages. Note: the composite endpoint was a 50% decline in eGFR and/or ESRD. (A) Kidney survival rates in CKD stage 1, 2, and 3 groups. (B) Kidney survival rates in SC and IT group patients with stage 1 CKD. (C) Kidney survival rates in SC and IT group patients with stage 2 CKD. (D) Kidney survival rates in SC and IT group patients with stage 3 CKD. SC = supportive care group; IT = corticosteroids/immunosuppressive therapy group.](medi-99-e20513-g006){#F3}

3.4. Predictive factors of renal outcome
----------------------------------------

Univariate analysis showed that hypertension, serum creatinine, eGFR, CKD stage at baseline, and the presence of segmental sclerosis (S1), tubular atrophy/interstitial fibrosis (T1/2), and glomerulosclerosis (G1/2) were significantly associated with increased renal outcome risk in this study. However, the multivariable model included only segmental sclerosis (HR 9.55, 95% CI 1.04--88.16, *P* = .047) and glomerulosclerosis (HR 21.09, 95% CI 1.39--320.53, *P* = .028) as independent predictive factors of renal survival (Table [4](#T4){ref-type="table"}).
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Cox Proportional Hazard Model for the primary endpoint in IgA nephropathy patients.
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4. Discussion
=============

IgAN is the most common cause of ESRD in adult patients with primary glomerulonephritis worldwide. It is generally thought that corticosteroid therapy may decrease the risk of progression in high-risk IgAN patients with eGFR \>50 mL/min per 1.73 m^2^ and proteinuria \>1 g/d despite 6 months of supportive therapy.^\[[@R4]\]^ However, the use of corticosteroids and immunosuppressive therapy in patients with mild proteinuria (\<1 g/d) has not been studied. Nam et al reported that the risk of developing adverse renal events was remarkably lower in patients with time-averaged proteinuria (TA-P) \< 1 g/d compared to those with TA-P \>1 g/d.^\[[@R8]\]^ Previous studies evaluating immunosuppressive therapy did not observe IgAN patients with proteinuria \< 1 g/d separately, although they included patients with proteinuria between 0.75 and 1 g/d.^\[[@R6],[@R9]\]^ Due to heterogeneous disease manifestation, various treatment strategies could be applied for patients with proteinuria \< 1 g/d. Therefore, we performed this study to analyze the effect of corticosteroids and immunosuppressive therapy in IgAN patients with mild proteinuria in order to inform choosing the optimal treatment strategy for IgAN patients.

Currently, there are no recommendations for the best IgAN treatment strategy due to controversial reports about corticosteroid and immunosuppressive therapy.^\[[@R10]\]^ The KDIGO guideline suggests corticosteroid use for patients with persistent proteinuria despite optimized RASi treatment. However, the evidence supporting this guideline is limited (2C).^\[[@R4]\]^ Moreover, corticosteroid or immunosuppressive therapy is also applied to a portion of IgAN patients with proteinuria \< 1 g/d because of active clinical or pathological manifestations such as cellular or fibrocellular crescents, necrotizing lesions, endocapillary proliferation, or a rapid decline of renal function. However, the risk of serious adverse events, such as severe infections and incapacitating bone and endocrine disorders, is notably higher during immunosuppressant use. Given that only a few published studies have discussed the effect of corticosteroid and immunosuppressive therapy in IgAN patients with mild proteinuria, it is difficult to weigh the benefits to long-term renal survival with the potential hazards.^\[[@R11]\]^ Recently, the STOP-IGAN trial, VALIGA cohort study, and several other studies indicated that corticosteroids/immunosuppressants had no desired benefits over renin angiotensin system blockade (RASB) treatment.^\[[@R6],[@R12],[@R13],[@R9]\]^ However, other studies found that corticosteroids/immunosuppressants could improve renal outcomes, such as increased proteinuria remission, decreased eGFR decline, and delayed progression to ESRD,^\[[@R14],[@R15],[@R16],[@R17]\]^ especially in Asian patients. In the present study, we found no favorable effect of corticosteroids or immunosuppressive therapy over optimal supportive care in IgAN patients with mild proteinuria. Moreover, Kaplan--Meier analysis also suggested that renal survival in SC and IT group patients was comparable (94.1% vs 93.7%, *P* = .808). These findings are concordant with the KDIGO guidelines. Therefore, based on our data, supportive care alone might be enough for IgAN patients with mild proteinuria (\< 1 g/d), and the addition of immunosuppressive drugs would not benefit these patients.

Our results suggested that baseline eGFR levels were associated with treatment group. We also observed that no stage 1 CKD patients with mild proteinuria progressed into ESRD during the follow-up period (49.46 ± 24.35 months). Prognosis of stage 1 CKD patients was significantly better than those in stage 2 or 3. It should be noted that only a small number of stage 3 CKD patients were recruited in this study. Nevertheless, the CR rate in stage 3 CKD patients in the IT group (71.4%) was much higher than in the SC group (21.1%) (*P* = .028). Furthermore, no stage 3 CKD patient in the IT group reached ESRD, while 5 patients in the SC group (26.3%) ended in ESRD. This finding is consistent with previous reports^\[[@R16]\]^ that immunosuppressive treatment, compared with supportive treatment, may improve short-term renal outcomes in advanced IgAN patients. However, the small number of stage 3 CKD patients enrolled in this study potentially biased these results.

Prior studies have noted the importance of pathological changes on kidney disease prognosis. Most previous studies focused on the association of segmental sclerosis, tubular atrophy/interstitial fibrosis (T), and renal survival.^\[[@R7]\]^ Recently, several reports have shown that global glomerulosclerosis is an independent risk factor for ESRD of IgAN.^\[[@R18]\]^ In accordance with previous results, we found that segmental sclerosis (HR 9.55, 95% CI 1.04--88.16) and glomerulosclerosis (HR 21.09, 95% CI 1.39--320.53) were significantly associated with renal outcome using Cox multivariate analysis. However, no significant differences were observed between patients in the SC and IT groups in S0 (99.4% vs 95.2%, *P* = .105), S1 (90.9% vs 96.4%, *P* = .370), G0 (99.5% vs 100.0%, *P* = .741), or G1/G2 (70.4% vs 88.2%, *P* = .247) according to Kaplan--Meier analysis of segmental sclerosis and glomerulosclerosis subgroups. Therefore, additional studies are required to confirm these findings (Table [4](#T4){ref-type="table"}).

This study had a few notable limitations. This was a small size retrospective study and all participants were Chinese. Thus, these results should be interpreted with caution, especially if extrapolating to other patient populations. Errors or missing data are inevitable. A longer follow-up period (more than 10 years) may be needed to achieve more definitive conclusions due to the slow progression of IgAN. Therefore, large-scale, multicenter, long-term follow up clinical studies are needed to achieve a more scientific management of IgAN patients.

5. Conclusion
=============

The results of this study indicate that corticosteroids or immunosuppressants were not superior to optimal supportive care in IgA nephropathy patients with mild proteinuria.
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